S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023

Eyenovia Stock Price, News & Analysis (NASDAQ:EYEN)

$1.42
-0.04 (-2.74%)
(As of 11/29/2023 ET)
Compare
Today's Range
$1.40
$1.52
50-Day Range
$1.08
$1.72
52-Week Range
$1.05
$5.85
Volume
320,143 shs
Average Volume
316,265 shs
Market Capitalization
$62.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Eyenovia MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
604.2% Upside
$10.00 Price Target
Short Interest
Bearish
4.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Eyenovia in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$12,411 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.68) to ($0.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

750th out of 949 stocks

Pharmaceutical Preparations Industry

365th out of 443 stocks


EYEN stock logo

About Eyenovia Stock (NASDAQ:EYEN)

Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

EYEN Stock Price History

EYEN Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Eyenovia's Stock Is Soaring Today - Here's Why
Billionaire Marc Lasry’s Top 10 Stock Picks
H.C. Wainwright Keeps Their Buy Rating on Eyenovia (EYEN)
See More Headlines
Receive EYEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYEN
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+604.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-28,010,000.00
Pretax Margin
-2,541,699.75%

Debt

Sales & Book Value

Annual Sales
$14 million
Book Value
$0.36 per share

Miscellaneous

Free Float
40,680,000
Market Cap
$62.65 million
Optionable
Not Optionable
Beta
1.75
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report














EYEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eyenovia stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYEN shares.
View EYEN analyst ratings
or view top-rated stocks.

What is Eyenovia's stock price target for 2024?

3 Wall Street research analysts have issued 12 month price objectives for Eyenovia's shares. Their EYEN share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 604.2% from the stock's current price.
View analysts price targets for EYEN
or view top-rated stocks among Wall Street analysts.

How have EYEN shares performed in 2023?

Eyenovia's stock was trading at $1.63 at the beginning of 2023. Since then, EYEN stock has decreased by 12.9% and is now trading at $1.42.
View the best growth stocks for 2023 here
.

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,960,000 shares, an increase of 12.0% from the October 31st total of 1,750,000 shares. Based on an average daily volume of 266,200 shares, the days-to-cover ratio is currently 7.4 days.
View Eyenovia's Short Interest
.

When is Eyenovia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our EYEN earnings forecast
.

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same quarter in the prior year, the company earned ($0.23) earnings per share.

What other stocks do shareholders of Eyenovia own?
When did Eyenovia IPO?

(EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (8.08%), Financial Management Network Inc. (0.21%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bren Kern, Charles E Iv Mather, Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev.
View institutional ownership trends
.

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EYEN) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -